APTN-101 / Adaptin Bio - LARVOL DELTA

Enrollment has opened in a first-in-human Phase I trial of APTN-101, an EGFRvIII-targeted bispecific T cell engager developed by Charlotte, North Carolina-based Adaptin Bio, Inc. (OTCQB: APTN) for patients with World Health Organization Grade IV malignant glioma (AllSci Corp) - "The trial is being conducted at Duke University's Preston Robert Tisch Brain Tumor Center, where the underlying BRiTE (Brain Bispecific T cell Engager) technology was developed. APTN-101 is designed to address two major barriers to immunotherapy in glioblastoma (GBM): drug penetration across the blood-brain barrier (BBB) and selective targeting of tumor cells."

Enrollment open • First-in-human • Glioma

Adaptin Bio…announced that the Preston Robert Tisch Brain Tumor Center has granted the first Institutional Review Board (IRB) approval for the Company’s Phase 1 first-in-human clinical trial evaluating APTN-101 in the treatment of glioblastoma multiforme (GBM) (GlobeNewswire)

First-in-human • New P1 trial • Glioblastoma

Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement (GlobeNewswire) - "Adaptin Bio, Inc...announced today the successful completion of a reverse merger of a wholly owned subsidiary of Unite Acquisition 1 Corp. with and into Adaptin, with Adaptin continuing as the surviving entity. Adaptin Bio expects to trade on the OTC Markets...In connection with the merger, Adaptin completed a private placement for the issuance and sale of 1,400,342 shares of its common stock and accompanying Series A warrants and Series B warrants. The Series A warrants will have a 1-year term, and an exercise price of $4.40 per common share. The Series B warrants will have a 5-year term, and an exercise price of $6.60 per common share....Adaptin currently intends to use the net proceeds from the private placement to advance the development of its investigational candidate APTN-101 for the treatment of glioblastoma, to design and advance other early-stage drug product candidates for undisclosed rare and unmet needs, and for working capital, capital expenditures..."

Financing • Glioblastoma

Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma (Businesswire) - "Adaptin Bio...has emerged from stealth today with the announcement that FDA has cleared an Investigational New Drug (IND) application for its APTN-101 program in glioblastoma (GBM), the most common and aggressive primary brain tumor. The clearance will enable the initiation of a first-in-human Phase 1 clinical trial to evaluate this investigational candidate in GBM....The Phase 1 clinical trial will assess the safety and efficacy of APTN-101 in patients diagnosed with WHO Grade IV Malignant Glioma, also known as GBM."

IND • New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor